Article Text
Statistics from Altmetric.com
QUESTION: In patients with cancer and venous thromboembolism (VTE), is a fixed dose of subcutaneous low molecular weight (LMW) heparin better than oral warfarin for secondary prophylaxis of VTE?
Design
Randomised {allocation concealed*}†, blinded {outcome assessors and data analysts}†,* controlled trial with primary follow up to 3 months.
Setting
25 centres in France.
Patients
146 patients >18 years of age (mean age 66 y, 55% women) with cancer of any type and deep venous thrombosis and/or pulmonary embolism. Exclusion criteria were previous heparin induced thrombocytopenia, allergy to iodine, pregnancy, fibrinolytic treatment within 3 days, oral anticoagulant use for >5 days, treatment with full dose heparin for this episode of VTE, major pulmonary embolism with shock, life expectancy <3 months, contraindication to anticoagulants, severe hepatic failure, planned major surgery or …
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.